Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 11Neoplasms 8Carcinoid Tumor 7Diarrhea 6Colorectal Neoplasms 6Carcinoma, Hepatocellular 5Vipoma 4Stomach Neoplasms 4Somatostatinoma 4Rectal Neoplasms 4Insulinoma 4Glucagonoma 4Gastro-enteropancreatic neuroendocrine tumor 4Carcinoma, Islet Cell 4Breast Neoplasms 4Adenoma, Islet Cell 4Acromegaly 4Weight Loss 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Intestinal Obstruction 3Gastrinoma 3Esophageal Neoplasms 3Colonic Neoplasms 3Carcinoma 3Thymoma 2Pituitary Neoplasms 2Ovarian Neoplasms 2Meningioma 2

Interventions

Fluorouracil 26Radiotherapy 17Mitomycin 17Cisplatin 12Capecitabine 12pembrolizumab 10Cyclophosphamide 9Radiation 8Paclitaxel 8fludarabine 7Specimen Handling 7Nivolumab 7Carboplatin 7Magnetic Resonance Spectroscopy 6Cetuximab 6Biopsy 6Papillomavirus Vaccines 5Drug Therapy 5dehydroftorafur 4aldesleukin 4Vaccines 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Watchful Waiting 3Taxes 3Oxaliplatin 3Observation 3Light Coagulation 3Ipilimumab 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Anus Neoplasms × Octreotide × Clear all
NCT00075868 2015-11-17

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
233 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡